Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study
dc.contributor.author | Dewaraja, Yuni K. | en_US |
dc.contributor.author | Wilderman, Scott J. | en_US |
dc.contributor.author | Koral, Kenneth F. | en_US |
dc.contributor.author | Kaminski, Mark S. | en_US |
dc.contributor.author | Avram, Anca M. | en_US |
dc.date.accessioned | 2010-10-14T14:20:34Z | |
dc.date.available | 2010-10-14T14:20:34Z | |
dc.date.issued | 2009-08 | en_US |
dc.identifier.citation | Dewaraja, Yuni K.; Wilderman, Scott J.; Koral, Kenneth F.; Kaminski, Mark S.; Avram, Anca M. (2009/08). "Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study." Cancer Biotherapy & Radiopharmaceuticals, 24(4): 417-426 <http://hdl.handle.net/2027.42/78152> | en_US |
dc.identifier.issn | 1084-9785 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78152 | |
dc.description.abstract | Abstract Integrated systems combining functional (single-photon emission computed tomography; SPECT) imaging with anatomic (computed tomography; CT) imaging have the potential to greatly improve the accuracy of dose estimation in radionuclide therapy. In this article, we present the methodology for highly patient-specific tumor dosimetry by utilizing such a system and apply it to a pilot study of 4 follicular lymphoma patients treated with I-131 tositumomab. SPECT quantification included three-dimensional ordered-subset expectation-maximization reconstruction and CT-defined tumor outlines at each time point. SPECT/CT images from multiple time points were coupled to a Monte Carlo algorithm to calculate a mean tumor dose that incorporated measured changes in tumor volume. The tumor shrinkage, defined as the difference between volumes drawn on the first and last CT scan (a typical time period of 15 days) was in the range 5%-49%. The therapy-delivered mean tumor-absorbed dose was in the range 146-334cGy. For comparison, the therapy dose was also calculated by assuming a static volume from the initial CT and was found to underestimate this dose by up to 47%. The agreement between tracer-predicted and therapy-delivered tumor-absorbed dose was in the range 7%-21%. In summary, malignant lymphomas can have dramatic tumor regression within days of treatment, and advanced imaging methods allow for a highly patient-specific tumor-dosimetry calculation that accounts for this regression. | en_US |
dc.format.extent | 442114 bytes | |
dc.format.extent | 3100 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Mary Ann Liebert, Inc. | en_US |
dc.title | Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study | en_US |
dc.type | Article | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 19694576 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78152/1/cbr.2008.0568.pdf | |
dc.identifier.doi | 10.1089/cbr.2008.0568 | en_US |
dc.identifier.source | Cancer Biotherapy & Radiopharmaceuticals | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.